塞力斯医疗科技集团股份有限公司 投资者关系管理制度 塞力斯医疗科技集团股份有限公司 投资者关系管理制度 （2025年8月） 第一章 总则 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"）与投 资者之间的信息沟通，促进投资者对公司的了解和认同，促进公司诚信自律、规 范运作，保持诚信、公正、透明的对外形象，更好地服务于投资者，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司投资者关系管理工作 指引》《上海证券交易所股票上市规则》（以下简称"《上市规则》"）、《上海 证券交易所上市公司自律监管指引第1号——规范运作》及其他适用法律、法规、 规范性文件以及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司 章程》"）的规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 公司控股股东、实际控制人以及董事和高级管理人员应当高度重视、 积极参与和 ...

塞力斯医疗科技集团股份有限公司 内部控制制度 塞力斯医疗科技集团股份有限公司 内部控制制度 （2025年8月） 第一章 总则 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"）内 部控制，促进公司规范运作和健康发展，保护投资者合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》 等法律法规的规定，结合公司的实际情况，制定本制度。 第二条 公司内部控制制度的目的： （一）遵守国家法律、法规、规章及其他相关规定； （二）提高公司经营的效益及效率，提升公司质量，增加对公司股东的回 报； （三）保障公司资产的安全、完整； （四）确保公司信息披露的真实、准确、完整和公平。 第三条 公司董事会应对公司内部控制制度的制定和有效执行负责。 第二章 内部控制的内容 第四条 公司的内部控制主要包括：环境控制、业务控制、会计系统控制、 信息传递控制、内部审计控制等内容。 第五条 公司应不断完善公司治理结构，确保董事会和股东会等机构合法运 作和科学决策，公司将逐步建立有效的激励约束机制，树立风险防范意识，培 育良好的企业精神和内部控制文化，创造全体职工充分了解并履行职责的环境。 ...

Core Viewpoint - The internal audit system of Selis Medical Technology Group Co., Ltd. aims to standardize internal audit work, clarify the responsibilities of internal audit institutions and personnel, and enhance internal control, operational management, and economic efficiency [1]. Group 1: Internal Audit Definition and Structure - Internal audit refers to the evaluation activities conducted by the company's internal audit institution or personnel to assess the effectiveness of internal control and risk management, the authenticity and completeness of financial information, and the efficiency and effectiveness of operational activities [1]. - The internal audit department must maintain independence and should not be under the leadership of the finance department or share office space with it [1][2]. Group 2: Responsibilities and Duties of Internal Audit - The internal audit institution is responsible for checking and evaluating the completeness, rationality, and effectiveness of internal control systems across the company and its subsidiaries [12]. - It must audit the legality, compliance, authenticity, and completeness of accounting and economic data, including financial reports and performance forecasts [12]. - The internal audit department should report to the audit committee at least quarterly, covering the execution of the internal audit plan and issues discovered during the audit [12]. Group 3: Audit Procedures and Reporting - The internal audit institution must submit the next year's internal audit work plan to the audit committee two months before the end of each accounting year and an annual audit report two months after the year-end [13]. - The internal audit process includes planning, execution, and reporting, with a focus on obtaining sufficient, relevant, and reliable audit evidence to support conclusions and recommendations [34][12]. Group 4: Internal Control Evaluation - Internal audit should evaluate the effectiveness of internal controls related to financial reporting and information disclosure, including the establishment and implementation of internal control systems [18]. - The internal audit institution must supervise the implementation of corrective measures for any identified internal control deficiencies [19]. Group 5: Rights and Powers of Internal Audit - The internal audit institution has the authority to formulate internal audit regulations, participate in financial management meetings, and request relevant documents from the audited entities [28][29]. - It can also take necessary measures against individuals obstructing the audit process and report significant issues promptly [30][31]. Group 6: Confidentiality and Ethics - Internal audit personnel must adhere to professional ethics, maintain confidentiality regarding audit matters, and avoid conflicts of interest [8][9]. - Any discovered serious violations or fraudulent activities must be reported to the relevant authorities for corrective action [37].

塞力斯医疗科技集团股份有限公司 募集资金管理办法 塞力斯医疗科技集团股份有限公司 募集资金管理办法 （2025 年 8 月） 第一章 总则 第一条 为完善塞力斯医疗科技集团股份有限公司（以下简称"公司"）治 理，规范公司对募集资金的使用和管理，提高募集资金的使用效率和效益，根据 《中华人民共和国公司法》 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等法律法规、规章、规范性文 件及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有权益性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划 募集的资金。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 公司存在两次以上融资的，应当分别设置募集资金专户。超募资金也应当存 放于募集资金专户管理。 募集资金投资境外项目的，除符合第一款规定外，公司及保荐机构还应当采 取有效措施，确保投资于境外项目的募集资 ...

塞力斯医疗科技集团股份有限公司 董事会议事规则 塞力斯医疗科技集团股份有限公司 董事会议事规则 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"）董 事会的决策行为和运作程序，保证公司决策行为的民主化、科学化，建立适应现 代市场经济规律和要求的公司治理机制，完善公司的法人治理结构，根据《中华 人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》《上 海证券交易所股票上市规则》（以下简称"《上市规则》"）《上海证券交易所 上市公司自律监管指引第 1 号—规范运作》等有关法律法规、规范性文件以及《塞 力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定， 特制订本规则。 第二条 公司董事会由股东会选举产生，并对股东会负责。证券部负责处理 董事会日常事务。 第二章 董事会的组成和职权 第三条 董事由股东会选举或更换，并可在任期届满前由股东会解除其职务。 董事任期三年，任期届满，可连选连任。 董事任期从就任之日起计算，至本届董事会任期届满时为止。董事任期届满 未及时改选，在改选出的董事就任前，原董事仍应当依照法律、行政法规、部门 规 ...

General Principles - The management control of the holding subsidiaries aims to establish an effective control mechanism to manage the company's governance structure, assets, and resources, enhancing overall operational efficiency and risk resistance [2][3][4] - The company exercises shareholder rights through voting and appointing directors, supervisors, and senior management to the holding subsidiaries, while also providing guidance, supervision, and related services [2][3] Management of Holding Subsidiaries - Holding subsidiaries must establish operational plans and risk management procedures in accordance with the company's business strategy and risk management policies [3][4] - Holding subsidiaries are required to report significant business and financial matters to the company in a timely manner, following the company's major matters reporting system [3][4][5] Establishment and Governance Structure - The establishment of holding subsidiaries must comply with national laws and regulations, align with the company's development strategy, and avoid blind expansion [4][5] - Holding subsidiaries must develop their articles of association in consultation with other shareholders and establish a sound internal management system [5][6] Supervision and Management - The company has the right to audit and inspect the operations and finances of holding subsidiaries, providing corrective recommendations as necessary [8][9] - Holding subsidiaries must adhere to the company's unified financial management policies and accounting systems, with the company's finance department overseeing their financial management [8][9] Information Disclosure - Significant events occurring in holding subsidiaries are treated as significant events for the company, requiring timely reporting to the company's board of directors [10][11] - The heads of holding subsidiaries are responsible for reporting information that may significantly impact the company's stock and derivatives trading prices [10][11]

General Principles - The company establishes a decision-making system for related party transactions to ensure fairness and reasonableness in transactions with related parties, in compliance with relevant laws and regulations [2][3][4] - The internal control of related party transactions should adhere to principles of honesty, equality, voluntariness, fairness, and openness, protecting the interests of all shareholders, especially minority shareholders [2][3] Definition of Related Parties and Transactions - Related parties include both legal entities and natural persons that have significant control or ownership over the company, such as those holding more than 5% of shares [5][6] - Related party transactions encompass various activities, including asset purchases, financial assistance, and service provisions [8][9] Decision-Making Authority for Related Transactions - Transactions exceeding certain thresholds, such as 3 million yuan or 0.5% of the latest audited net assets, require approval from a majority of independent directors and must be disclosed [9][10] - Transactions involving guarantees for related parties must receive approval from a supermajority of non-related directors and be submitted for shareholder meeting review [11][12] Pricing and Execution of Related Transactions - Related party transactions must be conducted at fair prices, with written agreements outlining pricing policies [29][30] - The company must ensure that related party transactions do not harm its interests or those of other shareholders, and must take measures to prevent related parties from monopolizing business channels [36][37] Information Disclosure - The company is required to disclose details of related party transactions, including the nature of the relationship, transaction terms, and pricing basis, in accordance with stock exchange regulations [38][39] - Annual and semi-annual reports must include significant related party transactions and their impacts on the company [27][28]

Core Viewpoint - The document outlines the behavior norms for the controlling shareholders and actual controllers of Celis Medical Technology Group Co., Ltd., aiming to enhance corporate governance, protect the rights of the company and its shareholders, and ensure compliance with relevant laws and regulations [2]. Group 1: General Principles - The norms are established to improve the corporate governance structure and regulate the actions of controlling shareholders and actual controllers [2]. - Controlling shareholders and actual controllers must adhere to the principles of honesty and credit, exercising shareholder rights and fulfilling obligations in accordance with laws and regulations [2]. - They are required to maintain the company's independence and not abuse their control to harm the interests of the company and other shareholders [2][3]. Group 2: Corporate Governance - Controlling shareholders and actual controllers must ensure the integrity of company assets and maintain independence in personnel, finance, organization, and business operations [3][4]. - They are prohibited from affecting the company's asset integrity through unfair practices, such as sharing production systems or using company assets without proper compensation [3][4]. - The independence of company personnel must be maintained, and controlling shareholders cannot influence personnel decisions outside of their legal rights [5][6]. Group 3: Financial Independence - Controlling shareholders and actual controllers must not use company funds for non-operational purposes or require the company to provide illegal guarantees [5][6]. - They are prohibited from sharing financial accounts or systems that could compromise the company's financial independence [5][6]. Group 4: Information Disclosure - Controlling shareholders and actual controllers must fulfill their information disclosure obligations accurately and completely, avoiding any false statements or omissions [9][10]. - They are required to establish clear procedures for reporting significant undisclosed information and maintain confidentiality regarding insider information [10][11]. Group 5: Share Trading and Control Transfer - Controlling shareholders must comply with legal regulations when trading shares and report any significant changes in shareholding promptly [11][12]. - They are required to ensure that any transfer of control is fair and does not harm the interests of the company or other shareholders [12][15]. Group 6: Other Provisions - Controlling shareholders and actual controllers must not engage in actions that could directly or indirectly infringe upon the company's assets or interests [29][30]. - They are responsible for ensuring that their commitments are enforceable and must provide guarantees for commitments with significant performance risks [31][32].

塞力斯医疗科技集团股份有限公司 经理工作细则 （2025 年 8 月） 第一章 总则 第一条 为促进塞力斯医疗科技集团股份有限公司（以下简称"公司"）经 营管理的制度化、规范化、科学化，确保公司经营决策的正确性、合理性，提高 民主决策、科学决策水平，根据《中华人民共和国公司法》 （以下简称" 《公司法》"） 等法律法规、规章、规范性文件及《塞力斯医疗科技集团股份有限公司章程》 （以 下简称"《公司章程》"）的规定，制订本细则。 第二条 公司依法设置经理（即总裁，下同）、副经理（即副总裁，下同） 和财务总监等高级管理人员，公司高级管理人员应当遵守法律、行政法规和《公 司章程》的规定，履行诚信和勤勉的义务，如负责公司的日常经营管理，经理对 公司董事会负责并报告工作，副经理、财务总监等高级管理人员对经理负责并报 告工作。 第三条 经理、副经理及其他高级管理人员在履行职务时，接受审计委员会 在遵守法律、法规和《公司章程》等方面的监督。 第二章 经理的任免 塞力斯医疗科技集团股份有限公司 经理工作细则 第四条 经理任职，应当具备下列条件: （一）优秀的个人品质：有责任心，积极进取、忠实勤勉、廉洁奉公等。 （二）良好的职 ...

塞力斯医疗科技集团股份有限公司 会计师事务所选聘制度 塞力斯医疗科技集团股份有限公司 会计师事务所选聘制度 第四条 公司控股股东、实际控制人和持有公司 5%以上股份的股东不得向 公司指定会计师事务所，不得干预公司审计委员会、董事会及股东会独立履行审 核职责。 第二章 会计师事务所执业质量要求 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"）选 聘、续聘以及改聘（以下合称"选聘"）会计师事务所的行为，切实维护股东利 益，提高审计工作和财务信息的质量，根据《中华人民共和国证券法》《国有企 业、上市公司选聘会计师事务所管理办法》《上海证券交易所股票上市规则》等 法律、行政法规、部门规章、规范性文件以及《塞力斯医疗科技集团股份有限公 司章程》（以下简称"《公司章程》"）的规定，特制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。 公司聘任会计师事务所从事除财务会计报告审计之外的其他法定审计业务 的，可以比照本制度执行。 第三条 公司选聘或解聘会计师事务所，应当由董事会 ...